BioXcel Therapeutics/$BTAI
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About BioXcel Therapeutics
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Ticker
$BTAI
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
37
ISIN
US09075P2048
Website
BTAI Metrics
BasicAdvanced
$10M
-
-$12.28
0.08
-
Price and volume
Market cap
$10M
Beta
0.08
52-week high
$6.83
52-week low
$1.17
Average daily volume
338K
Financial strength
Current ratio
1.479
Quick ratio
1.214
Long term debt to equity
-110.808
Total debt to equity
-117.416
Interest coverage (TTM)
-3.27%
Profitability
EBITDA (TTM)
-50.433
Gross margin (TTM)
-12.15%
Net profit margin (TTM)
-2,163.17%
Operating margin (TTM)
-2,739.74%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-52.47%
Return on equity (TTM)
49.30%
Valuation
Price to revenue (TTM)
3.046
Price to book
-0.1
Price to tangible book (TTM)
-0.1
Price to free cash flow (TTM)
-0.085
Free cash flow yield (TTM)
-1,176.33%
Free cash flow per share (TTM)
-2,034.93%
Growth
Revenue change (TTM)
5.47%
Earnings per share change (TTM)
-85.10%
3-year earnings per share growth (CAGR)
-42.85%
BTAI News
AllArticlesVideos
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewsWire·3 weeks ago
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioXcel Therapeutics stock?
BioXcel Therapeutics (BTAI) has a market cap of $10M as of June 20, 2025.
What is the P/E ratio for BioXcel Therapeutics stock?
The price to earnings (P/E) ratio for BioXcel Therapeutics (BTAI) stock is 0 as of June 20, 2025.
Does BioXcel Therapeutics stock pay dividends?
No, BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next BioXcel Therapeutics dividend payment date?
BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders.
What is the beta indicator for BioXcel Therapeutics?
BioXcel Therapeutics (BTAI) has a beta rating of 0.08. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.